MicuRx Of China Chooses First Antibiotic For Development
This article was originally published in PharmAsia News
Executive Summary
China's MicuRx Pharmaceuticals says it plans to conduct its first development effort on its MRX-I molecule to fight bacteria, including staphylococcus aureas, that are resistant to several drugs. The firm is readying the drug for preclinical trials while it expands its Chinese operations to increase its capacity to develop the medicine and other drugs in its pipeline. MicuRx plans another generation of antimicrobial products the expanded facilities would be designed to handle. Shengyu Yuan, MicuRx CEO, said the company has discovered several multiple-drug leads, and said MRX-I was a promising compound it expects to be superior to many top-selling antibiotics. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.